The success of Amgen R&D can be seen in our product portfolio, which includes novel therapies for hard-to-treat diseases. These therapies have been used to treat more than 25 million patients worldwide with diseases that include cancer, kidney failure, blood and autoimmune disorders, and bone diseases. We are building on these successes with a drug pipeline that aims to help patients with conditions such as heart disease, schizophrenia, and migraine.